Episode 67: Spotlight - Head and Neck Cancer: Docetaxel as a radiosensitiser

Cisplatin is the mainstay for concurrent chemoradiotherapy in Locally Advanced Head and Neck Cancers. What happens to that significant group of patients who cannot have cisplatin? Michael and Josh focus on this challenging subgroup of patients. Can docetaxel be used as an alternative? This week, they debut a small but significant segment of our humble podcast called "Spotlight", where we dive deep into a single potentially practice-changing trial. Enjoy!

Links to studies discussed in this episode (subscription may be required):

Docetaxel as a radiosensitiser: https://ascopubs.org/doi/abs/10.1200/jco.22.00980#:~:text=We%20found%20that%20the%20use,of%20life%20of%20the%20patients.